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Abstract 
Fluoxetine is a serotonin specific reuptake inhibitor anti-depressant and is the only 
approved pharmacological treatment for major depressive disorder (MDD) in 
children and adolescent. We searched the published randomized controlled-trials 
(RCT) to review fluoxetine efficacy and tolerability using the databases PubMed, 
EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials 
for fluoxetine role in managing MDD in children and adolescents. A meta-analysis 
was conducted using the identified 7 clinical trials to assess efficacy using the 
outcomes: Children’s Depression Rating Scale-Revised (CDRS-R), Clinical Global 
Impressions – Severity of Illness (CGI-S) and Clinical Global Impressions – 
Improvement (CGI-I) response rate. The risk of discontinuation due to adverse 
effects and common side effects were examined. The mean difference in change 
from baseline for CDRS-R was -2.72 [95% Confidence Interval (CI) -3.96, -1.48] 
favouring fluoxetine treatment (p<0.001). Similarly, mean difference for CGI-S was 
-0.21 [95% CI -0.36, -0.06]. The risk ratio (RR) of discontinuing due to adverse 
events was 0.98 [95% CI 0.54, 1.83], with RR for headache side effects 1.34 [95% 
CI 1.03, 1.74] and rash 2.6 [95% CI 1.32, 5.14].  Fluoxetine demonstrates 
significant improvements in symptom intensity control in young patients suffering 
from MDD and is considered well-tolerated with similar rates of trials 
discontinuation; however, fluoxetine was associated with a higher risk of 
headache and rash side effects. These findings will guide psychiatrists and 




Depression is characterised by low mood and loss of pleasure 1 with symptoms 
including reduced concentration, feeling of guilt, negative thoughts and disturbed 
sleep 2. According to DSM-5 3, individuals must be experiencing five or more 
symptoms (depressed mood, diminished interest or pleasure, significant weight 
loss, slowing down of thought and a reduction of physical movement, fatigue, 
feelings of worthlessness or excessive or inappropriate guilt, diminished ability to 
think or concentrate and recurrent suicidal ideation) during 2-week period with at 
least either depressed mood or loss of interest/pleasure as a core symptom 4.  
Worldwide, over 260 million suffer from depressive disorders - a main cause of 
disability - leading to difficulties in social functioning and suicide 5. In children and 
adolescents, depression increased incidence of alcohol consumption, drug use 
and self-harm 6.  Alcohol abuse has been shown to decrease serotonin levels 
leading to deteriorating of the depressive symptoms and increased suicide 
incidence 7. For a diagnosis of depression to be made, the patient must have 
experienced symptoms for most of the day for 2 weeks 1, while International 
Statistical Classification of Diseases (ICD-10) classifies depression into three main 
categories: mild, moderate and severe. Depression in adults is diagnosed using 
psychiatric scales such as Beck Depression Inventory (BDI), while clinician rated 
scale such as Children’s Depression Rating Scale –Revised (CDRS-R) are used 
for children/adolescents 8. 
A variety of antidepressants have shown efficacy in depression management in 
adults, including tricyclic antidepressants (TCAs), selective serotonin re-uptake 
inhibitors (SSRIs), serotonin and noradrenaline re-uptake inhibitors (SNRIs) and 
monoamine oxidase inhibitors (MAOIs) 9. In contrast, few studies have been 
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conducted in young people, where it is recommended that pharmacological therapy 
is initiated once psychological treatment is in use. SSRIs are the first-line 
pharmacological therapy in young people and currently, fluoxetine is the only 
licensed anti-depressant for adolescents in the UK 1. On the other hand, there are 
some concerns regarding association of SSRI with suicide incidence in children and 
adolescents 10-12. 
SSRIs inhibit the neurotransmitter 5-hydroxytryptamine (serotonin) reuptake into 
serotoninergic neurones, leading to increased serotonin level in the synapse. 
Compared to TCAs, SSRI cause less anticholinergic side effects and are safer in 
overdose 9. SSRI are also indicated for the management of co-morbid anxiety and 
obsessive-compulsive disorder (OCD) 9.  Fluoxetine is relatively long-acting with a 
half-life of 1 - 3 days, which could increase further to 4 to 6 days following chronic 
administration 13 and is extensively sequestered in tissues 14. Fluoxetine is mainly 
metabolised via the CYP2D6 pathway in the liver to the active metabolite 
norfluoxetine (half-life ~ 9 days) 13. The aim of the systematic meta-analysis is to 
update knowledge regarding fluoxetine efficacy and safety compared to placebo in 
children and adolescents diagnosed with MDD. 
Methods 
Search strategy 
The focussed research question: “Will fluoxetine compared with placebo lower the 
severity of depression and alter adverse effects’ incidence in children and 
adolescents with MDD”.  
The study population included children and adolescent patients taking part in RCT’s 
assigned to either fluoxetine or placebo for the management of MDD. A literature 
search was performed for RCT’s investigating the efficacy and/or safety of 
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fluoxetine compared to placebo. The search terms ‘fluoxetine, placebo, major 
depressive disorders’ were used in PubMed, ScienceDirect, EUDRACT, 
ClinicalTrials.gov and Cochrane Central Register of Controlled Trials up to 
September 2019 with filters applied such as ‘clinical trials’ and ‘child/adolescents’. 
No restrictions on study size, year of study or duration were set. Titles were 
screened for relevance, duplicates removed, then abstracts screened before the 
remaining relevant full texts were examined to find those meeting the inclusion 
criteria (Figure 1). 
Efficacy and Tolerability Outcomes  
The primary efficacy outcomes of included RCT were measured using self-report or 
clinician-rated scales, where generally, clinician-rated scales are more reliable. One 
of the most commonly used scales was CDRS-R, a clinician-rated scale used to 
measure the severity of depression 15, which contains 17 items in total, 14 of which 
were rated from 1 to 7 with the remaining 3 rated from 1 to 5 with a total score can 
range from 17-113 8. Clinical Global Impressions-Severity of Illness Score (CGI-S), 
a clinician rated scale, was also used for depressive symptoms severity 16.  The 
primary tolerability and safety outcomes for fluoxetine were discontinuation due to 
adverse effects and side effects.  
Statistical analysis 
Review Manager 5.3 (RevMan) along with the Cochrane Collaboration tool for 
assessing the risk of bias 17, 18 were used to assess the levels of selection, 
performance, detection, attrition and reporting bias in each of the chosen RCT’s. 
‘Characteristics of study’ tables were completed in RevMan for each of the individual 
studies and a summary table was created 18. 
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The inverse variance method with fixed effects model was used to calculate the 
mean differences for continuous outcomes. The Mantel-Haenszel method with 
random effects model used to calculate the risk ratio for dichotomous outcomes 
(Risk of discontinuation due to adverse effects and side effects) 19 using RevMan, 
95% confidence intervals was determined. p-value <0.05 was regarded as 
statistically significant 18. Variations can occur between trials as they will differ in 
aspects such as participants, interventions and outcomes 20, thus, a test for 
heterogeneity was carried out using chi-squared (Chi2) test and I2 value. 
Results 
Search results and included studies 
Figure 1 shows the selection process of included RCT’s. PubMed, EUDRACT, 
ClinicalTrials.gov and Cochrane Central Register of Controlled Trials were searched 
for ‘Fluoxetine’ giving 2441 records in total. After removing duplicates and screening 
titles and abstracts, 24 studies were included in full text screening, while 7 RCTs 
met the inclusion criteria 21-27. Table 1 shows the characteristics of the included 
published randomized controlled trials that investigated the tolerability, safety or 
efficacy of fluoxetine in patients suffering from MDD, a total of 1259 patients were 
included in the studies analysed within this review.  All RCTs were double blinded 
and placebo-controlled with treatment duration range 6 to 10 weeks. Studies were 
undertaken in regions including USA, Russia with similar prevalence and incidence 
rates to the UK 28.  Trials containing serious co-morbidities, including diagnosis of 
other DSM-IV defined disorders such as bipolar disorder, psychotic depression or 
substance abuse disorder were excluded. 
Figure 2 shows the risk of bias with the sequence generation, allocation 
concealment and blinding mostly with ‘unclear’ risk due to insufficient information. 
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The patients in all the studies were randomly assigned and there was certain level 
of blinding for both participants and personnel. The domains relating to the 
completeness of data and reporting of outcomes were ‘low’ risk of bias, while other 
risks were high due to the high extent of trials funding/support by pharmaceutical 
companies (Figure 2).  
Efficacy of Fluoxetine in Children and Adolescents Major Depressive 
Disorders 
The mean change from baseline in CDRS-R was -2.72 [95% Confidence Interval 
(CI) -3.96, -1.48] favouring fluoxetine treatment (p<0.001), with a total of 601
fluoxetine patients and 592 placebo patients included in the analysis (Figure 3a). 
The forest plot shows the MD for all the studies individually favor fluoxetine with 
some degree of heterogeneity between the studies (x2=16.52, I2=70%). The mean 
difference (MD) for CGI-S was -0.21 with 95% CI -0.36 to -0.06 (Figure 3b) favoring 
fluoxetine. Atkinson show data not consistent with the other trials regarding CGI-S, 
with high heterogeneity between the studies (x2=17.81, I2=78%). CGI response rate 
was higher in fluoxetine compared to placebo, with a risk ratio (RR) =1.46 [1.27 to 
1.67] (Figure 3c) and moderate heterogeneity between trials (x2=4.36, I2=31%).  
Only two RCTs 23, 24 measured the effect of fluoxetine on CDRS mood, somatic and 
behaviour subscales (Figure 3d, 3e and 3f) with the overall result showed a positive 
effect for fluoxetine on all three subscales with MD from baseline -2.65 [95% CI -
3.77, -1.52], -2.48 [95% CI -3.61, -1.34], -1.77 [95% CI -2.6, -0.94] respectively with 
low to moderate heterogeneity among the studies. 
Tolerability and Safety of Fluoxetine in Children and Adolescents Major 
Depressive Disorders 
The overall risk ratio for trial discontinuation due to adverse effects is 0.99 [0.54 to 
1.83], p=0.98, showing no major differences between fluoxetine and placebo groups 
(Figure 4a), with some variation among the studies with some favouring fluoxetine, 
and others favouring placebo (I2 = 12%).  There was no significant statistical 
difference in the total incidence of side effects between fluoxetine and placebo 
(p=0.52) (Figure 4b). Fluoxetine was associated with some mild side effects 
including headache RR=1.34 [1.03 to 1.74], p=0.03 and rash RR=2.60 [1.32 to 
5.14], p=0.006 (Figure 4). For the other side effects such as suicidal ideation, 
dizziness, sedation, nausea and vomiting, no significant statistical differences were 
detected between fluoxetine and placebo.  
Discussion and Conclusion 
This systematic review/meta-analysis investigated the efficacy and safety of 
fluoxetine for the management of MDD in children and adolescents using the 
available clinical trials. Fluoxetine improved CDRS-R total psychiatric scale used for 
measuring symptom severity in young patients with depression. Fluoxetine also 
showed significant improvements in CGI-S and CGI-I response rate. This meta-
analysis update knowledge regarding the role of fluoxetine as it is currently, the only 
antidepressant licensed for use in children and adolescents. These results are 
consistent with a previous meta-analysis that showed fluoxetine and escitalopram 
the only treatments with possible efficacy as anti-depressants in children and 
adolescents 29. These results (Figure 3) confirmed the efficacy of fluoxetine as 
highlighted in other meta-analyses covering several antidepressants and showing 
a moderate beneficial role of fluoxetine in MDD 30, 31. Another meta-analysis casted 
doubt on the role of fluoxetine in MDD in children and adolescents 32; however, new 
data included from recent trials are included in this article supports fluoxetine 
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efficacy. Risk of discontinuing was similar in fluoxetine compared to placebo with 
equal risk of total side effects in the fluoxetine treatment compared to placebo.   
These results confirm that there were insignificant changes in treatment emergent 
suicidal thoughts with fluoxetine, in agreement with previous research 29. Generally, 
these findings focused on fluoxetine as anti-depressant in the management of MDD 
supported and updated other researchers’ work 33 that showed efficacy consistent 
with these findings even in adults 34. Furthermore, these findings showed fluoxetine 
efficacy as a pharmacological treatment of MDD in children and adolescents 35, 
while including a recent large scale clinical trial 27.  Results (Figure 4) also show that 
fluoxetine was associated with mild side effects such as headache (RR=1.34) and 
Rash (RR=2.6). This review shows that fluoxetine is well tolerated and significantly 
improves MDD in children and adolescents.  The results need to be interpreted with 
caution as the treatment length ranged from just 6 to 10 weeks, with not enough 
evidence for long-term treatment effects, while several doses of fluoxetine were 
used with different efficacy and side effects profile. Therefore, it is recommended 
that further research using different doses with long-term treatment is conducted for 
a more comprehensive understanding of the role of fluoxetine in the management 
of MDD.  
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Table 1 Randomized Controlled trials included in the meta-analysis 
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Figure 1: Prisma Flow chart for literature search results of fluoxetine versus 
placebo in major depressive disorder for children and adolescents. 
Figure 2: Risk of bias summary and methodological quality graph: review authors' 
judgements about each risk of bias item for each included study and each 
methodological quality item presented as percentages across all included studies. 
Figure 3: Efficacy outcomes measures for Fluoxetine versus placebo in the 
management of major depressive disorder for children and adolescents. A. 
Outcome: CDRS-R total score changes. B. CGI-S total score changes. C. CGI-I 
response rate. D. CDRS-R subscale – mood total score changes. E. CDRS-R 
subscale – somatic total score changes F. CDRS-R subscale – behavior total 
score changes CDRS-R: Children's Depression Rating Scale, Revised... CGI-S: 
Clinical Global Impressions – Severity. CGI-I: Clinical Global Impression scale-
Improvement (CGI-I).  
Figure 4: Tolerability and safety profile of fluoxetine compared to placebo. A. 
Outcome: Trial Withdrawal Due to adverse Event. B. Outcome: Total incidence of 
Side Effects. C. Outcome: Side Effect - Headache. D. Outcome: Side Effect - 
Rash. 
